BACKGROUND: Pulmonary arterial hypertension (PAH) is characterized by dysregulated proliferation of pulmonary artery smooth muscle cells leading to (mal)adaptive vascular remodeling. In the systemic circulation, vascular injury is associated with downregulation of sarcoplasmic reticulum Ca(2+)-ATPase 2a (SERCA2a) and alterations in Ca(2+) homeostasis in vascular smooth muscle cells that stimulate proliferation. We, therefore, hypothesized that downregulation of SERCA2a is permissive for pulmonary vascular remodeling and the development of PAH. METHODS AND RESULTS: SERCA2a expression was decreased significantly in remodeled pulmonary arteries from patients with PAH and the rat monocrotaline model of PAH in comparison with controls. In human pulmonary artery smooth muscle cells in vitro, SERCA2a overexpression by gene transfer decreased proliferation and migration significantly by inhibiting NFAT/STAT3. Overexpresion of SERCA2a in human pulmonary artery endothelial cells in vitro increased endothelial nitric oxide synthase expression and activation. In monocrotaline rats with established PAH, gene transfer of SERCA2a via intratracheal delivery of aerosolized adeno-associated virus serotype 1 (AAV1) carrying the human SERCA2a gene (AAV1.SERCA2a) decreased pulmonary artery pressure, vascular remodeling, right ventricular hypertrophy, and fibrosis in comparison with monocrotaline-PAH rats treated with a control AAV1 carrying β-galactosidase or saline. In a prevention protocol, aerosolized AAV1.SERCA2a delivered at the time of monocrotaline administration limited adverse hemodynamic profiles and indices of pulmonary and cardiac remodeling in comparison with rats administered AAV1 carrying β-galactosidase or saline. CONCLUSIONS: Downregulation of SERCA2a plays a critical role in modulating the vascular and right ventricular pathophenotype associated with PAH. Selective pulmonary SERCA2a gene transfer may offer benefit as a therapeutic intervention in PAH.
BACKGROUND:Pulmonary arterial hypertension (PAH) is characterized by dysregulated proliferation of pulmonary artery smooth muscle cells leading to (mal)adaptive vascular remodeling. In the systemic circulation, vascular injury is associated with downregulation of sarcoplasmic reticulum Ca(2+)-ATPase 2a (SERCA2a) and alterations in Ca(2+) homeostasis in vascular smooth muscle cells that stimulate proliferation. We, therefore, hypothesized that downregulation of SERCA2a is permissive for pulmonary vascular remodeling and the development of PAH. METHODS AND RESULTS: SERCA2a expression was decreased significantly in remodeled pulmonary arteries from patients with PAH and the ratmonocrotaline model of PAH in comparison with controls. In human pulmonary artery smooth muscle cells in vitro, SERCA2a overexpression by gene transfer decreased proliferation and migration significantly by inhibiting NFAT/STAT3. Overexpresion of SERCA2a in human pulmonary artery endothelial cells in vitro increased endothelial nitric oxide synthase expression and activation. In monocrotalinerats with established PAH, gene transfer of SERCA2a via intratracheal delivery of aerosolized adeno-associated virus serotype 1 (AAV1) carrying the human SERCA2a gene (AAV1.SERCA2a) decreased pulmonary artery pressure, vascular remodeling, right ventricular hypertrophy, and fibrosis in comparison with monocrotaline-PAHrats treated with a control AAV1 carrying β-galactosidase or saline. In a prevention protocol, aerosolized AAV1.SERCA2a delivered at the time of monocrotaline administration limited adverse hemodynamic profiles and indices of pulmonary and cardiac remodeling in comparison with rats administered AAV1 carrying β-galactosidase or saline. CONCLUSIONS: Downregulation of SERCA2a plays a critical role in modulating the vascular and right ventricular pathophenotype associated with PAH. Selective pulmonary SERCA2a gene transfer may offer benefit as a therapeutic intervention in PAH.
Authors: Sifeng Chen; Matthias Kapturczak; Scott A Loiler; Sergei Zolotukhin; Olena Y Glushakova; Kirsten M Madsen; Richard J Samulski; William W Hauswirth; Martha Campbell-Thompson; Kenneth I Berns; Terence R Flotte; Mark A Atkinson; C Craig Tisher; Anupam Agarwal Journal: Hum Gene Ther Date: 2005-02 Impact factor: 5.695
Authors: A P Fishman; M C Fishman; B A Freeman; M A Gimbrone; M Rabinovitch; D Robinson; D B Gail Journal: Am J Respir Crit Care Med Date: 1998-08 Impact factor: 21.405
Authors: S E Harding; U Schmidt; T Matsui; Z B Kang; G W Dec; J K Gwathmey; A Rosenzweig; R J Hajjar Journal: Circulation Date: 1999-12-07 Impact factor: 29.690
Authors: Masakuni Kido; Lingling Du; Christopher C Sullivan; Reena Deutsch; Stuart W Jamieson; Patricia A Thistlethwaite Journal: J Thorac Cardiovasc Surg Date: 2005-02 Impact factor: 5.209
Authors: Benjamin Strauss; Yassine Sassi; Carlos Bueno-Beti; Zeki Ilkan; Nour Raad; Marine Cacheux; Malik Bisserier; Irene C Turnbull; Erik Kohlbrenner; Roger J Hajjar; Lahouaria Hadri; Fadi G Akar Journal: J Mol Cell Cardiol Date: 2018-11-28 Impact factor: 5.000
Authors: Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri Journal: Mol Ther Date: 2019-12-06 Impact factor: 11.454
Authors: Jaume Aguero; Kiyotake Ishikawa; Lahouaria Hadri; Carlos G Santos-Gallego; Kenneth M Fish; Erik Kohlbrenner; Nadjib Hammoudi; Changwon Kho; Ahyoung Lee; Borja Ibáñez; Ana García-Alvarez; Krisztina Zsebo; Bradley A Maron; Maria Plataki; Valentin Fuster; Jane A Leopold; Roger J Hajjar Journal: J Am Coll Cardiol Date: 2016-05-03 Impact factor: 24.094
Authors: Igor B Gubrij; Sara Rebecca Martin; Amanda K Pangle; Richard Kurten; Larry G Johnson Journal: Hum Gene Ther Date: 2014-03-26 Impact factor: 5.695